BUDAPEST, HUNGARY, June 4, 2022 /EINPresswire.com/

Omixon Biocomputing, Kft announced today that it has completed a collaborative agreement with Organ Monitoring Group to develop post-transplant monitoring product HoloGRAFT. As part of the agreement Omixon secured an exclusive option to acquire all remaining shares of Organ Monitoring Group BV (OMG) after having acquired 50% of OMG. Organ Monitoring Group BV owns some exclusive license rights to commercialize patented methods using copy-number-variant markers using digital polymerase chain reaction (dPCR) technology for transplant monitoring. The method was developed and validated by John Whitlam, MD, PhD, Clinical Lead, Kidney Transplantation at Austin Health, and colleagues at the Murdoch Children’s Research Institute in Melbourne, Australia. Omixon will fund collaborative development programs related to transplant monitoring applications while Mr Doug Bost, Founder and CEO of OMG, joins Omixon as Member, Board of Directors, and Vice-President of Transplant Monitoring Products. Financial details of the transaction were not disclosed.

We are happy to announce that JETA Molecular celebrates 6th anniversary today. We thank to our partners, collaborators and customers for helping us to advance excellence in molecular diagnostics!

The HoloGRAFT™ kit, developed by JETA Molecular in cooperation with Omixon, detects cell-free, donor-derived circulating DNA as a biomarker of organ health after transplantation using the highly sensitive digital PCR (dPCR) technology. On April 11, 2022, the dPCR experts from JETA Molecular organized the World´s first demo at Children´s Hospital of Philadelphia (CHOP), US, using the QIAcuity Digital PCR System.

JETA Molecular is proud to announce its new collaboration with VH Bio Ltd, for our DigitalTRACE dPCR Stem Cell Monitoring Kits and Software.